Serologic markers of viral hepatitis A, B, C, and D in patients with hemophilia.
Forty-one patients with hemophilia A were studied for the prevalence of serological markers for hepatitis A, hepatitis B, hepatitis C (non-A and non-B hepatitis), and delta hepatitis (hepatitis D). Ten of 41 (24.4%) patients demonstrated hepatitis A antibody and 31 of 41 (75.6%) patients had a serologic marker for previous hepatitis B infection; four of these 31 patients (13%) also demonstrated antibody to delta agent (hepatitis D). Thirty-seven of 41 (90.2%) patients demonstrated antibody for hepatitis C. Nine of 31 (29%) patients with a hepatitis B marker (no hepatitis B vaccinees) were negative for anti-HBc but positive for anti-HBs; all of these nine patients were HIV antibody positive, although they had no overt immunodeficiency. Twenty-six of 41 (63.5%) patients were HIV antibody positive. Of HIV antibody positive patients, 27%, 88%, and 100% demonstrated evidence of a previous hepatitis A, hepatitis B, or hepatitis C, respectively. Of HIV antibody negative patients; 20%, 53%, and 73% of the patients demonstrated evidence of a previous hepatitis A, hepatitis B, or hepatitis C infections, respectively. The difference between HIV antibody positive and HIV antibody negative groups was not significant for hepatitis A but was significant for hepatitis B (P < 0.001) and hepatitis C (P < .001). Of the 31 patients with a hepatitis B serologic marker, all had antibody to hepatitis C. Of 10 patients, without a hepatitis B serologic marker, only 6 (60%) had antibody to hepatitis C.(ABSTRACT TRUNCATED AT 250 WORDS)
Kumar
A
A
Department of Pediatrics & Human Development, Michigan State University, East Lansing 48824-1317.
Kulkarni
R
R
Murray
D L
DL
Gera
R
R
Scott-Emuakpor
A B
AB
Bosma
K
K
Penner
J A
JA
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D006679:HIV Seropositivity / Q000150:complications; D006467:Hemophilia A / Q000150:complications*; D016174:Hepacivirus / Q000276:immunology; D006506:Hepatitis A / Q000150:complications* / Q000453:epidemiology; D017957:Hepatitis A Virus, Human / Q000276:immunology; D006508:Hepatitis Antibodies / Q000097:blood*; D006509:Hepatitis B / Q000150:complications* / Q000453:epidemiology; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000276:immunology; D006526:Hepatitis C / Q000150:complications* / Q000453:epidemiology; D003699:Hepatitis D / Q000150:complications* / Q000453:epidemiology; D003698:Hepatitis Delta Virus / Q000276:immunology; D006801:Humans; D007223:Infant; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D014481:United States / Q000453:epidemiology
D006508:Hepatitis Antibodies; D006514:Hepatitis B Surface Antigens